Venous Thromboembolism Associated with CD19-directed CAR T-cell Therapy in Large B-cell Lymphoma

Overview

Journal Blood Adv

Specialty Hematology

Date 2020 Sep 3

PMID 32877523

Citations 18

Authors

Hamza Hashmi

Abu-Sayeef Mirza

Alicia Darwin

Constantine Logothetis

Franco Garcia

Anuhya Kommalapati

Rahul S Mhaskar

Christina Bachmeier

Julio C Chavez

Bijal Shah

Javier Pinilla-Ibarz

Farhad Khimani

Aleksandr Lazaryan

Hien Liu

Marco L Davila

Frederick L Locke

Taiga Nishihori

Michael D Jain

Affiliations

Soon will be listed here.

Citing Articles

Cardiovascular toxicity of tisagenlecleucel in children and adolescents: analysis of spontaneous reports submitted to FAERS.

Wang G, Su L, Liu Y, Yang X, Li Y, Mei Q Front Immunol. 2025; 16:1499143.

PMID: 39911387 PMC: 11794787. DOI: 10.3389/fimmu.2025.1499143.

Epidemiology, Pathophysiology, and Management of Cancer-Associated Ischemic Stroke.

Ryan D, Bou Dargham T, Ikramuddin S, Shekhar S, Sengupta S, Feng W Cancers (Basel). 2024; 16(23).

PMID: 39682202 PMC: 11640599. DOI: 10.3390/cancers16234016.

Development and validation of predictive models of early immune effector cell-associated hematotoxicity.

Liang E, Huang J, Portuguese A, Ortiz-Maldonado V, Albittar A, Wuliji N Blood Adv. 2024; 9(3):606-616.

PMID: 39626349 PMC: 11847049. DOI: 10.1182/bloodadvances.2024014455.

Venous Thromboembolism Risk in Hematological Malignancies Post-Chimeric Antigen Receptor T-Cell (CAR-T) Therapy: A Meta-Analysis of Phase 2 and Phase 3 Clinical Trials.

Chitkara A, Sreenivasan S, Yin Y, Rai M, Sadashiv S Curr Oncol. 2024; 31(8):4338-4345.

PMID: 39195306 PMC: 11352860. DOI: 10.3390/curroncol31080323.

A systematic review and meta-analysis of nonrelapse mortality after CAR T cell therapy.

Cordas Dos Santos D, Tix T, Shouval R, Gafter-Gvili A, Alberge J, Cliff E Nat Med. 2024; 30(9):2667-2678.

PMID: 38977912 PMC: 11765209. DOI: 10.1038/s41591-024-03084-6.

References

Lee D, Gardner R, Porter D, Louis C, Ahmed N, Jensen M . Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014; 124(2):188-95. PMC: 4093680. DOI: 10.1182/blood-2014-05-552729. View

Locke F, Neelapu S, Bartlett N, Siddiqi T, Chavez J, Hosing C . Phase 1 Results of ZUMA-1: A Multicenter Study of KTE-C19 Anti-CD19 CAR T Cell Therapy in Refractory Aggressive Lymphoma. Mol Ther. 2017; 25(1):285-295. PMC: 5363293. DOI: 10.1016/j.ymthe.2016.10.020. View

Key N, Khorana A, Kuderer N, Bohlke K, Lee A, Arcelus J . Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer: ASCO Clinical Practice Guideline Update. J Clin Oncol. 2019; 38(5):496-520. DOI: 10.1200/JCO.19.01461. View

Taylor Jr F, Toh C, Hoots W, Wada H, Levi M . Towards definition, clinical and laboratory criteria, and a scoring system for disseminated intravascular coagulation. Thromb Haemost. 2002; 86(5):1327-30. View

Liu H, Yang Y, Jiang J, Wang X, Zhang C, Jiang Y . Coexistence Of A Huge Venous Thromboembolism And Bleeding Tendency In Cytokine Release Syndrome During CAR-T Therapy. Onco Targets Ther. 2019; 12:8955-8960. PMC: 6826178. DOI: 10.2147/OTT.S223697. View

Najem M, Couturaud F, Lemarie C . Cytokine and chemokine regulation of venous thromboembolism. J Thromb Haemost. 2020; 18(5):1009-1019. DOI: 10.1111/jth.14759. View

Zahid M, Murad M, Litzow M, Hogan W, Patnaik M, Khorana A . Venous thromboembolism following hematopoietic stem cell transplantation-a systematic review and meta-analysis. Ann Hematol. 2016; 95(9):1457-64. DOI: 10.1007/s00277-016-2673-3. View

Neelapu S, Tummala S, Kebriaei P, Wierda W, Gutierrez C, Locke F . Chimeric antigen receptor T-cell therapy - assessment and management of toxicities. Nat Rev Clin Oncol. 2017; 15(1):47-62. PMC: 6733403. DOI: 10.1038/nrclinonc.2017.148. View

Hegerova L, Bachan A, Cao Q, Vu H, Rogosheske J, Reding M . Catheter-Related Thrombosis in Patients with Lymphoma or Myeloma Undergoing Autologous Stem Cell Transplantation. Biol Blood Marrow Transplant. 2018; 24(12):e20-e25. PMC: 6526714. DOI: 10.1016/j.bbmt.2018.07.028. View

10.

Neelapu S, Locke F, Bartlett N, Lekakis L, Miklos D, Jacobson C . Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma. N Engl J Med. 2017; 377(26):2531-2544. PMC: 5882485. DOI: 10.1056/NEJMoa1707447. View

11.

Mohren M, Markmann I, Jentsch-Ullrich K, Koenigsmann M, Lutze G, Franke A . Increased risk of thromboembolism in patients with malignant lymphoma: a single-centre analysis. Br J Cancer. 2005; 92(8):1349-51. PMC: 8826296. DOI: 10.1038/sj.bjc.6602504. View

12.

Baron J, Gridley G, Weiderpass E, Nyren O, Linet M . Venous thromboembolism and cancer. Lancet. 1998; 351(9109):1077-80. DOI: 10.1016/S0140-6736(97)10018-6. View

13.

Kersten M, van Ettekoven C, Heijink D . Unexpected neurologic complications following a novel lymphoma treatment 'expected' to give rise to neurologic toxicity. BMJ Case Rep. 2019; 12(11). PMC: 6855863. DOI: 10.1136/bcr-2019-229946. View

14.

Levi M, Toh C, Thachil J, Watson H . Guidelines for the diagnosis and management of disseminated intravascular coagulation. British Committee for Standards in Haematology. Br J Haematol. 2009; 145(1):24-33. DOI: 10.1111/j.1365-2141.2009.07600.x. View

15.

Gust J, Hay K, Hanafi L, Li D, Myerson D, Gonzalez-Cuyar L . Endothelial Activation and Blood-Brain Barrier Disruption in Neurotoxicity after Adoptive Immunotherapy with CD19 CAR-T Cells. Cancer Discov. 2017; 7(12):1404-1419. PMC: 5718945. DOI: 10.1158/2159-8290.CD-17-0698. View

16.

Citla Sridhar D, Abou-Ismail M, Ahuja S . Central venous catheter-related thrombosis in children and adults. Thromb Res. 2020; 187:103-112. DOI: 10.1016/j.thromres.2020.01.017. View